CD24 and breast cancer: In addition, recent findings of McDonald et al. that no RUNX3 was detected in mammary epithelial populations sorted by FACS with CD29 and CD24 surface markers [41] indicate that potential toxicity driven by CADD522 could be minimal in BC patients.